VivoSeq
Dermatology

Prurigo Nodularis

25

Pipeline Programs↗

15

Active Trials↗

16

Companies Involved↗

Prurigo Nodularis is an emerging landscape with 25 programs across 16 companies. The most active players are Pfizer, Celldex Therapeutics, Roche. 2 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 2C

Celldex Therapeutics

2 programs

Phase 2Roche logo

Roche

2 programs

Phase 2Sanofi logo

Sanofi

3 programs

Phase 3V

Vyne Therapeutics Inc.

1 program

Phase 3T

Trevi Therapeutics

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

19 of 25 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody520%Vaccine14%

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

36

clinical trials

Completed18 · 50%
Recruiting9 · 25%
Active, not recruiting6 · 17%
Unknown status3 · 8%

Clinical Trials

Trial Activity

36 trials

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT07236099·135 enrolled
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 2/3·NCT06554509·236 enrolled
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Recruiting·Incyte logoIncyte·Phase 3·NCT06516965·330 enrolled
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
Recruiting·SShanghai Mabgeek Biotech.Co.Ltd·Phase 3·NCT06779136·160 enrolled
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
Recruiting·UUMC Utrecht·N/A·NCT07276425·40 enrolled
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
Recruiting·Sanofi logoSanofi·N/A·NCT06087627·150 enrolled
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Recruiting·Incyte logoIncyte·Phase 3·NCT06516952·330 enrolled
Upadacitinib for Prurigo Nodularis
Recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT06773403·25 enrolled
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Recruiting·Sanofi logoSanofi·Phase 3·NCT06293053·18 enrolled
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Active, not recruiting·Amgen logoAmgen·Phase 3·NCT06527404·469 enrolled
Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
Active, not recruiting·KKeymed Biosciences Co.Ltd·Phase 3·NCT06424470·200 enrolled
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
Active, not recruiting·Sanofi logoSanofi·N/A·NCT05991323·100 enrolled
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Active, not recruiting·GGalderma R&D·Phase 3·NCT04204616·500 enrolled
A Study of Barzolvolimab in Patients With Prurigo Nodularis
Active, not recruiting·CCelldex Therapeutics·Phase 2·NCT06366750·140 enrolled
OLYMPIA-PN: Nemolizumab in Prurigo Nodularis
Active, not recruiting·Pfizer logoPfizer·Phase 3·NCT06000004·350 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)